By Counterforce Health Team in Kymriah (tisagenlecleucel) —

Getting Kymriah Approved by UnitedHealthcare in Pennsylvania: Complete Coverage Guide with Appeals Process

Answer Box: Fast Track to Kymriah Coverage

UnitedHealthcare covers Kymriah (tisagenlecleucel) as a medical benefit requiring prior authorization through OptumHealth Transplant Solutions. Key requirements: CD19+ confirmed disease, ≥2 prior therapy failures, treatment at FACT-accredited center. First step today: Verify your plan includes transplant benefits and confirm your treatment center is UnitedHealthcare-certified. If denied, Pennsylvania's new Independent External Review Program has a 53% overturn rate. Submit appeals within 60 days internally, then within 4 months to Pennsylvania Insurance Department if needed.

Table of Contents

  1. Coverage Requirements at a Glance
  2. Step-by-Step: Fastest Path to Approval
  3. Prior Authorization Documentation
  4. Common Denial Reasons & Solutions
  5. Appeals Process in Pennsylvania
  6. Pennsylvania's External Review Advantage
  7. Cost Support Options
  8. Frequently Asked Questions

Coverage Requirements at a Glance

Requirement What It Means Where to Find It
Prior Authorization Medical benefit requiring pre-approval through OptumHealth Transplant Solutions UnitedHealthcare Provider Portal
Diagnosis Eligibility B-cell ALL (≤25 years), DLBCL, or FL with specific relapse/refractory criteria FDA Kymriah Label
CD19 Positivity Flow cytometry or immunohistochemistry confirmation required Lab reports from treating facility
Prior Therapies ≥2 systemic therapies with documented failure/intolerance Medical records with treatment dates and outcomes
Treatment Center FACT-accredited facility only Kymriah Treatment Center Locator
Appeal Deadlines 60 days internal; 4 months Pennsylvania external review Denial letter and PA Insurance Department

Step-by-Step: Fastest Path to Approval

1. Verify Plan Coverage (Patient/Family)

Timeline: 1-2 business days
Call UnitedHealthcare member services (number on your ID card) to confirm your plan includes transplant/cellular therapy benefits. Ask specifically about "CAR-T therapy coverage" and note the representative's name and reference number.

2. Confirm Treatment Center Network Status (Clinic Staff)

Timeline: 2-3 business days
Contact UnitedHealthcare provider relations to verify your preferred Pennsylvania CAR-T center is in-network. Key facilities include:

  • Penn Medicine Abramson Cancer Center
  • UPMC Hillman Cancer Center
  • Fox Chase-Temple University Hospital
  • Penn State Cancer Institute

3. Gather Required Documentation (Clinic Team)

Timeline: 1-2 weeks
Compile complete treatment history, CD19 positivity results, current staging, and ECOG performance status. Document all prior therapy failures with specific dates and reasons for discontinuation.

4. Submit Prior Authorization (Treatment Center)

Timeline: 5-15 business days for review
Submit through UnitedHealthcare Provider Portal as a medical service request. Include comprehensive clinical packet with letter of medical necessity addressing FDA-approved indications.

5. Peer-to-Peer Review (If Initial Denial)

Timeline: 24-48 hours
Request immediately via fax to Managed Pharmacy Consultations at 561-209-5822. Include clinical rationale and NCCN guideline references supporting medical necessity.

6. Internal Appeal (If Still Denied)

Timeline: 60 days to file, 30 days for decision
Submit formal appeal with additional clinical evidence and updated treatment urgency documentation through provider portal or fax per denial letter instructions.

7. Pennsylvania External Review (Final Step)

Timeline: 4 months to file, 45 days for decision
File with Pennsylvania Insurance Department after exhausting internal appeals. Include Final Adverse Benefit Determination letter and supporting medical records.

Prior Authorization Documentation Checklist

Medical Necessity Letter Must Include:

  • Patient demographics: Full name, DOB, policy number, ICD-10 diagnosis codes
  • Disease confirmation: CD19 positivity via flow cytometry (≥90% tumor expression preferred)
  • Treatment history: Chronological list with drug names, dates, duration, response outcomes (CR/PR/PD/stable)
  • Failure documentation: Specific reasons for prior treatment discontinuation (progression, intolerance, contraindications)
  • Current status: Disease burden, ECOG performance status, organ function assessments
  • Clinical rationale: Why patient meets FDA-approved indications per Kymriah prescribing information
  • Treatment plan: Bridging therapy approach, lymphodepletion protocol, administration timeline
  • Center certification: Confirmation of FACT accreditation and CAR-T program credentials
Clinician Corner: Include NCCN guideline references specific to your patient's diagnosis. For DLBCL, cite NCCN B-Cell Lymphomas guidelines supporting CAR-T in relapsed/refractory setting. Document any contraindications to alternative therapies like autologous stem cell transplant.

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
Missing CD19 positivity Submit flow cytometry or IHC results Lab report confirming CD19+ expression
Insufficient prior therapy Document all previous treatments with outcomes Complete treatment chronology with dates and responses
Non-certified treatment center Verify FACT accreditation or request single-case agreement Center certification documentation
Not medically necessary Emphasize FDA-approved indication match Clinical rationale per prescribing information
Investigational/experimental Reference FDA approval dates and indications FDA approval letter and current prescribing information

Most successful appeal strategy: Request peer-to-peer review immediately after denial. Clinical discussions with UnitedHealthcare medical directors result in 78-85% overturn rates for well-documented cases.

Appeals Process in Pennsylvania

Internal Appeals (Required First Step)

Commercial Plans:

  • Filing deadline: 60 days from denial date
  • Response time: 30 days (pre-service), 60 days (post-service)
  • Expedited option: 72 hours if health at risk
  • Submission: UnitedHealthcare Provider Portal or fax per denial letter

Medicare Advantage:

  • Filing deadline: 60 days from denial
  • Response time: 30 days standard, 72 hours expedited
  • Auto-escalation: Proceeds to Independent Review Entity if no decision within timeframe

Required Appeal Documentation:

  • Copy of original prior authorization request
  • Denial letter with reason codes
  • Updated letter of medical necessity
  • Additional clinical evidence (recent labs, imaging, progress notes)
  • Peer-reviewed literature supporting treatment
  • NCCN or other guideline references
Tip: Mark urgent appeals "EXPEDITED - URGENT" and document specific harm from treatment delay. Call 1-866-604-3267 to confirm expedited processing within 4-6 hours.

Pennsylvania's External Review Advantage

Pennsylvania launched its Independent External Review Program in January 2024, giving residents a powerful new tool for overturning insurance denials. Key advantage: 53% success rate in first year, with over 100 Pennsylvanians receiving coverage for initially denied treatments.

How Pennsylvania External Review Works:

Eligibility: Fully insured commercial plans (individual, Pennie marketplace, employer-sponsored). Excludes self-funded employer plans.

Timeline:

  • File within: 4 months of Final Adverse Benefit Determination
  • Standard review: Decision within 45 days
  • Expedited review: Decision within 72 hours for urgent cases

Process:

  1. Complete UnitedHealthcare's internal appeal process
  2. Receive Final Adverse Benefit Determination letter
  3. Submit external review request at PA Insurance Department portal
  4. Include supporting medical records within 15 days of assignment
  5. Independent medical reviewers evaluate case
  6. Binding decision - if approved, UnitedHealthcare must provide coverage immediately

Success Factors for CAR-T External Reviews:

  • Strong clinical documentation of treatment necessity
  • Clear demonstration that denial contradicts medical evidence
  • Emphasis on life-threatening nature of underlying cancer
  • Documentation of failed alternative treatments

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing payer policies, identifying denial weaknesses, and drafting evidence-backed rebuttals. Their platform helps patients and clinicians navigate complex prior authorization requirements for specialty therapies like CAR-T, significantly improving approval rates through targeted, policy-specific appeal strategies.

Cost Support Options

Novartis Patient Support Programs:

  • Novartis Oncology Access: Copay assistance up to $25,000 annually for eligible commercial insurance patients
  • Patient Assistance Program: Free drug for uninsured patients meeting income criteria
  • Case management: Dedicated support coordinators for insurance navigation

Pennsylvania-Specific Resources:

  • Pennsylvania Health Law Project: Free legal assistance with insurance appeals
  • Pennie marketplace: Premium tax credits and cost-sharing reductions for eligible individuals
  • Pennsylvania Insurance Department: Consumer assistance with coverage disputes

Foundation Grants:

  • Leukemia & Lymphoma Society: Patient aid programs for treatment-related expenses
  • CancerCare: Financial assistance and copay relief programs
  • National Foundation for Transplants: Fundraising and grant support for cellular therapies

Frequently Asked Questions

How long does UnitedHealthcare prior authorization take for Kymriah in Pennsylvania? Standard review takes 5-15 business days. Expedited review (for urgent cases) takes 24-72 hours. Submit requests early as manufacturing time adds 3-5 weeks to the overall timeline.

What if Kymriah isn't on UnitedHealthcare's formulary? Kymriah is covered as a medical benefit under transplant services, not as a pharmacy benefit. Coverage doesn't depend on formulary status but requires meeting medical necessity criteria.

Can I request expedited review if my cancer is progressing? Yes. Document disease progression, declining performance status, or risk of becoming ineligible for CAR-T. Call member services to request expedited processing and follow up with written documentation.

Does step therapy apply to CAR-T therapy? UnitedHealthcare requires documentation of ≥2 prior systemic therapy failures, but this aligns with FDA-approved indications rather than traditional step therapy. Focus on demonstrating relapsed/refractory status per prescribing information.

What happens if Pennsylvania external review rules in my favor? UnitedHealthcare must provide coverage immediately, including retroactive coverage if you paid out-of-pocket during the appeal. The decision is binding on the insurance company.

How do I find Pennsylvania CAR-T centers in UnitedHealthcare's network? Use UnitedHealthcare's provider directory online or call member services. Verify network status directly as CAR-T centers may have special contracted arrangements not reflected in standard directories.

From our advocates: "We've seen Pennsylvania's new external review program make a real difference for CAR-T denials. One family we worked with had UnitedHealthcare deny Kymriah for their teenager with relapsed ALL, claiming 'investigational status' despite clear FDA approval. After a strong external review submission emphasizing the FDA approval and clinical guidelines, the independent reviewer overturned the denial within 30 days. The key was comprehensive documentation and understanding that Pennsylvania reviewers are specifically trained to evaluate complex oncology cases."

When Treatment Centers Navigate Counterforce Health Support

Many Pennsylvania CAR-T centers work with specialized appeal platforms to improve their prior authorization success rates. These platforms analyze UnitedHealthcare's specific coverage policies, identify common denial patterns, and help draft targeted rebuttals that address payer concerns directly. For families facing denials, understanding how treatment centers leverage these tools can provide insight into the appeal process and improve confidence in pursuing coverage.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and clinical circumstances. Always consult with your healthcare team and insurance representatives for guidance specific to your situation. For assistance with insurance appeals in Pennsylvania, contact the Pennsylvania Insurance Department's Office of Consumer Services.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.